Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227458 | 0.85 | GPBAR1 (0.51) | SMN1; SMN2GAAGPBAR1 | |
| SCHEMBL274968 | 0.85 | GPBAR1 (0.51) | SMN1; SMN2GAAGPBAR1 | |
| SCHEMBL28640796 | 0.82 | IDO1 (0.49) | LMNASMN1; SMN2IDO1TDO2L3MBTL1 | |
| SCHEMBL794256 | 0.82 | IDO1 (0.49) | LMNASMN1; SMN2IDO1TDO2L3MBTL1 | |
| SCHEMBL26276948 | 0.75 | SMN1; SMN2 (0.62) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL5180974 | 0.74 | NAAA (0.58) | GAAGPBAR1ALDH1A1 | |
| SCHEMBL765661 | 0.74 | NAAA (0.58) | GAAGPBAR1ALDH1A1 | |
| SCHEMBL3930648 | 0.74 | NAAA (0.58) | GAAGPBAR1ALDH1A1 | |
| SCHEMBL8777371 | 0.74 | KMT2A (0.48) | MEN1KMT2AGPBAR1 | |
| SCHEMBL8745681 | 0.74 | IDO1 (0.47) | LMNASMN1; SMN2IDO1TDO2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994342-B2 | Method for producing optically active succinimide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7807846-B2 | such as 2-benzyloxycarbonylamino-2-ethoxycarbonyl succinimide by reacting aminomalonic ester with halo-containing amide in solvent (ethanol) in presence of sodium ethoxide; intermediates, raw materials for industrial scale production of drugs; cost efficiency | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20100003729-A1 | Method for producing optically active succinimide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004464-A1 | Method for producing succinimide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2077261-A1 | METHOD FOR PRODUCING SUCCINIMIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-2071033-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004464-A1 | Method for producing succinimide compound | ALDH7A1, SDHB, SDHA | LMNA 2353/4885SMN1; SMN2 445/4885IDO1 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.